Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
41351070 (PubMed )
Supplement: 12885_2025_15187_MOESM1_ESM.zip › Supp_Table_1.xlsx › Sheet1
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
Irani S et al.
The Journal of Clinical Investigation, 2024
37883178 (PubMed )
Supplement: jci-134-163242-s231.xlsx › TableS5
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P et al.
Scientific Reports, 2019
30728399 (PubMed )
Supplement: 41598_2018_37574_MOESM1_ESM.pdf
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
Katzenellenbogen JA et al.
Nature Reviews. Cancer, 2018
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Toy W et al.
Cancer Discovery, 2017
PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Dong Y et al.
Human Pathology, 2012
[Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Select a paper to view details